Zobrazeno 1 - 6
of 6
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Juan C. Paramo, Sajeve S. Thomas, William Schmidt, Pallavi Kumar, Eddy C. Hsueh, Deepti Behl, Vinay Kumar Gupta, Prejesh Philips, Edward C. McCarron, Arvinda Padmanabhan, Adam C. Berger, Daniel Milton, Tawnya L. Bowles, Robert Weber, Jeffrey B Travers, Brendan D. Curti, Suthee Rapisuwon, Robert H.I. Andtbacka, Peter D. Beitsch, Mohammed M. Milhem, Edward A. Levine, John R. Hyngstrom, Suprith Badarinath, Anna Bar, John Keech, Marcus O. Butler, Omid Hamid, Brian R. Gastman, Andrew L. Pecora, Craig L. Slingluff, Takami Sato, J. Thaddeus Beck, Sekwon Jang, Catalin Mihalcioiu, John A. Glaspy, Karl D. Lewis, Shernan G. Holtan, Joël Claveau, Montaser Shaheen, Leonel Hernandez-Aya, Jose Lutzky, Brent A. Blumenstein, Joanna J Peterkin, Svetomir N. Markovic, Sujith Kalmadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMost patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plu
Autor:
J. Thaddeus Beck, Christian U. Blank, Angela Zubel, Adnan Derti, Heidi Nauwelaerts, Carola Berking, Victor Antona, Michael Heinrich, Dirk Schadendorf, Reinhard Dummer, Rupam Ranjan Pal, Sanjiv S. Agarwala, Rob L. H. Jansen, Carla M.L. van Herpen, Axel Hauschild, Paola Queirolo, Paolo A. Ascierto
Publikováno v:
OncoTarget, 10(19), 1850-1859. Impact Journals LLC
Scopus-Elsevier
Oncotarget
Oncotarget, 10, 19, pp. 1850-1859
Oncotarget, 10, 1850-1859
Scopus-Elsevier
Oncotarget
Oncotarget, 10, 19, pp. 1850-1859
Oncotarget, 10, 1850-1859
BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAFV600-mutant melanoma. We perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b26652bb8787171333752b989c125a0
https://www.ncbi.nlm.nih.gov/pubmed/30956763
https://www.ncbi.nlm.nih.gov/pubmed/30956763
Autor:
S. Spence McCachren, James Moon, J. Thaddeus Beck, Nerses S. Tchekmedyian, Robert P. Whitehead, Vernon K. Sondak, Evan M. Hersh, Wolfram E. Samlowski
Publikováno v:
Cancer. 100:1699-1704
BACKGROUND Single-agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed first-line therapy and might benefit from additional
Autor:
Simon Wandel, Paola Queirolo, Carla M.L. van Herpen, Reinhard Dummer, Malte Peters, Angela Zubel, Sanjiv S. Agarwala, Dirk Schadendorf, Carola Berking, Faiz Niazi, Annie St-Pierre, J. Thaddeus Beck, Christian U. Blank, Axel Hauschild, Paolo A. Ascierto
Publikováno v:
Lancet Oncology, 14, 249-56
Lancet Oncology, 14, 3, pp. 249-56
Lancet Oncology, 14, 3, pp. 249-56
Summary Background Patients with melanoma harbouring Val600 BRAF mutations benefit from treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF wild-type tumours, including those with NRAS mutations. We aimed to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20dd3fe26f0f4a90b24d506d4dce09bf
https://www.ncbi.nlm.nih.gov/pubmed/23414587
https://www.ncbi.nlm.nih.gov/pubmed/23414587
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sanjiv S. Agarwala, Christian U. Blank, Simon Wandel, Paola Queirolo, J. Thaddeus Beck, Carla M.L. van Herpen, Axel Hauschild, Paolo A. Ascierto, Angela Zubel, Carola Berking, Dirk Schadendorf, Faiz Niazi, Reinhard Dummer
Publikováno v:
Web of Science
Publons
Publons
8511 Background: BRAF and NRAS mutations occur in 50-60% and 15-20% of cutaneous melanomas, respectively. MEK162, a selective inhibitor of the kinases MEK1 and MEK2, has shown pre-clinical activity in BRAF and NRAS mutant (mt) melanoma models. This o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53bdac2a41f4e2b22fd6a11db2471c45
https://publons.com/wos-op/publon/11232815/
https://publons.com/wos-op/publon/11232815/